COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY

被引：0
|
作者：
Jozsa, Z. [1 ]
Toth, E. [2 ]
Nagy, B. [2 ]
机构：
[1] Novo Nordisk Hungary Ltd, Budapest, Hungary
[2] Healthware Ltd, Budapest, Hungary
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72090-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [31] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY CLINICAL DRIVERS IN COST-EFFECTIVENESS ANALYSES IN T2DM PATIENTS UNCONTROLLED ON CURRENT THERAPIES
    Afonso, M.
    Gupta, J.
    Kamra, S.
    Jasso-Mosqueda, J.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [32] Designing a new therapy for T2DM
    Claire Greenhill
    Nature Reviews Endocrinology, 2019, 15 : 684 - 684
  • [33] Insulin plus metformin for T2DM—are there benefits?
    Clifford J. Bailey
    Nature Reviews Endocrinology, 2012, 8 : 449 - 450
  • [34] Insulin Secretion and Sensitivity Pattern Is Different in patients With T2DM Only or Patients With T2DM and NAFLD
    Pan, Xiaoyu
    Liu, Qing
    Song, Kexiu
    Chai, Shangyu
    Li, Fei
    Huang, Yueye
    Bhavna, Bhavna
    Jhummon, Navina Priya
    Qu, Shen
    DIABETES, 2013, 62 : A492 - A492
  • [35] Neural Basis for an Association of Heightened Impulsivity with Insulin Resistance in Obesity Associated T2DM
    Eckstrand, Kristen
    Cowan, Ronald
    Silver, Heidi
    Niswender, Kevin Dean
    Avison, Malcolm
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [36] FDA approves Fiasp insulin for T1DM and T2DM
    不详
    NURSE PRACTITIONER, 2018, 43 (01): : 56 - 56
  • [37] STRUCTURED GLUCOSE MONITORING AS PREDICTOR OF EFFECTIVENESS AND SAFETY OF INSULIN TREATMENT IN T2DM PATIENTS
    Strongin, L.
    Petrov, A.
    Suvorova, L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A164 - A165
  • [38] Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
    Priyadi, Akhmad
    Permana, Hikmat
    Muhtadi, Ahmad
    Sumiwi, Sri A.
    Sinuraya, Rano K.
    Suwantika, Auliya A.
    HEALTHCARE, 2021, 9 (02)
  • [39] COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARY
    Nemeth, T.
    Tabak, A.
    Ban, A.
    Bacskai, M.
    Tarcsa, M.
    VALUE IN HEALTH, 2018, 21 : S128 - S128
  • [40] DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK
    Aguiar-Ibanez, R.
    Palencia, R.
    Kandaswamy, P.
    Flavin, J.
    Gauthier, A.
    Davies, M. J.
    VALUE IN HEALTH, 2014, 17 (07) : A562 - A562
12345